The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI)

22 May 2014 11:28

RNS Number : 8204H
Goldman Sachs & Co.
22 May 2014
 

 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

(GS) GOLDMAN, SACHS & CO.

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

ASTRAZENECA PLC

(d) Date position held/dealing undertaken:

21 May 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

USD 0.25 ordinary and ADRs

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

11,110

0.00

299,900

0.02

(2) Derivatives (other than options):

160

0.00

0

0.00

(3) Options and agreements to purchase/sell:

2,091,800

0.16

513,100

0.04

 

TOTAL:

2,103,070

0.16

813,000

0.06

 

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

ADR

Purchase

100

72.9400 USD

ADR

Purchase

100

73.1600 USD

ADR

Purchase

100

73.1800 USD

ADR

Purchase

200

73.2600 USD

ADR

Purchase

100

73.3100 USD

ADR

Purchase

100

73.3100 USD

ADR

Purchase

100

73.3500 USD

ADR

Purchase

200

73.3600 USD

ADR

Purchase

25

73.4000 USD

ADR

Purchase

100

73.4000 USD

ADR

Purchase

78

73.4000 USD

ADR

Purchase

100

73.4000 USD

ADR

Purchase

171

73.4100 USD

ADR

Purchase

200

73.4300 USD

ADR

Purchase

200

73.4300 USD

ADR

Purchase

100

73.4700 USD

ADR

Purchase

100

73.4700 USD

ADR

Purchase

100

73.5000 USD

ADR

Purchase

100

73.5000 USD

ADR

Purchase

200

73.5000 USD

ADR

Purchase

100

73.5000 USD

ADR

Purchase

100

73.5000 USD

ADR

Purchase

200

73.5000 USD

ADR

Purchase

100

73.5100 USD

ADR

Purchase

100

73.5100 USD

ADR

Purchase

100

73.5300 USD

ADR

Purchase

200

73.5300 USD

ADR

Purchase

200

73.5400 USD

ADR

Purchase

100

73.5500 USD

ADR

Purchase

100

73.5500 USD

ADR

Purchase

100

73.5500 USD

ADR

Purchase

200

73.5500 USD

ADR

Purchase

100

73.5800 USD

ADR

Purchase

100

73.5800 USD

ADR

Purchase

100

73.5800 USD

ADR

Purchase

100

73.6000 USD

ADR

Purchase

200

73.6000 USD

ADR

Purchase

100

73.6000 USD

ADR

Purchase

100

73.6000 USD

ADR

Purchase

100

73.6000 USD

ADR

Purchase

100

73.6100 USD

ADR

Purchase

46

73.6100 USD

ADR

Purchase

100

73.6100 USD

ADR

Purchase

100

73.6100 USD

ADR

Purchase

200

73.6400 USD

ADR

Purchase

200

73.6600 USD

ADR

Purchase

100

73.6800 USD

ADR

Purchase

2

73.6800 USD

ADR

Purchase

98

73.6800 USD

ADR

Purchase

200

73.7000 USD

ADR

Purchase

100

73.7400 USD

ADR

Purchase

100

73.7500 USD

ADR

Purchase

100

73.7600 USD

ADR

Purchase

100

73.7600 USD

ADR

Purchase

100

73.8200 USD

ADR

Purchase

100

73.8400 USD

ADR

Purchase

100

73.8500 USD

ADR

Purchase

100

73.9000 USD

ADR

Purchase

100

73.9800 USD

ADR

Purchase

100

74.0500 USD

ADR

Purchase

100

74.0600 USD

ADR

Purchase

200

74.0800 USD

ADR

Purchase

100

74.1000 USD

ADR

Purchase

100

74.1000 USD

ADR

Purchase

200

74.1600 USD

ADR

Purchase

100

74.2100 USD

ADR

Purchase

100

74.2100 USD

ADR

Purchase

200

74.2200 USD

ADR

Purchase

200

74.2200 USD

ADR

Purchase

100

74.2200 USD

ADR

Purchase

100

74.2300 USD

ADR

Purchase

100

74.2300 USD

ADR

Purchase

200

74.2700 USD

ADR

Purchase

200

74.2700 USD

ADR

Purchase

200

74.3600 USD

ADR

Purchase

30

74.4200 USD

ADR

Purchase

100

74.4200 USD

ADR

Purchase

100

74.4200 USD

ADR

Purchase

81

74.4300 USD

ADR

Purchase

200

74.4600 USD

ADR

Purchase

100

74.4700 USD

ADR

Purchase

100

74.4900 USD

ADR

Purchase

200

74.5300 USD

ADR

Purchase

100

74.5400 USD

ADR

Purchase

100

74.5900 USD

ADR

Purchase

100

74.5900 USD

ADR

Purchase

100

74.6300 USD

ADR

Purchase

118

74.6400 USD

ADR

Purchase

100

74.6400 USD

ADR

Purchase

100

74.6400 USD

ADR

Purchase

100

74.7700 USD

ADR

Purchase

200

74.8000 USD

ADR

Purchase

200

74.8100 USD

ADR

Purchase

100

74.8100 USD

ADR

Purchase

100

74.8300 USD

ADR

Purchase

100

74.8300 USD

ADR

Purchase

100

74.8300 USD

ADR

Purchase

200

74.8400 USD

ADR

Purchase

100

74.8400 USD

ADR

Purchase

100

74.8400 USD

ADR

Purchase

100

74.8500 USD

ADR

Purchase

100

74.8500 USD

ADR

Purchase

100

74.8600 USD

ADR

Purchase

200

74.8700 USD

ADR

Purchase

30

74.8800 USD

ADR

Purchase

100

74.9000 USD

ADR

Purchase

100

74.9800 USD

ADR

Purchase

100

75.1500 USD

ADR

Purchase

100

75.2200 USD

ADR

Sale

100

72.9700 USD

ADR

Sale

100

73.2000 USD

ADR

Sale

10

73.2000 USD

ADR

Sale

100

73.2600 USD

ADR

Sale

100

73.3200 USD

ADR

Sale

20

73.3200 USD

ADR

Sale

100

73.3400 USD

ADR

Sale

100

73.3500 USD

ADR

Sale

100

73.3600 USD

ADR

Sale

200

73.3600 USD

ADR

Sale

200

73.3900 USD

ADR

Sale

100

73.3900 USD

ADR

Sale

100

73.3900 USD

ADR

Sale

100

73.4000 USD

ADR

Sale

200

73.4000 USD

ADR

Sale

200

73.4000 USD

ADR

Sale

200

73.4200 USD

ADR

Sale

100

73.4200 USD

ADR

Sale

100

73.4200 USD

ADR

Sale

100

73.4300 USD

ADR

Sale

100

73.4300 USD

ADR

Sale

200

73.4400 USD

ADR

Sale

200

73.4500 USD

ADR

Sale

200

73.4700 USD

ADR

Sale

18

73.4900 USD

ADR

Sale

100

73.5000 USD

ADR

Sale

100

73.5000 USD

ADR

Sale

100

73.5000 USD

ADR

Sale

200

73.5000 USD

ADR

Sale

100

73.5100 USD

ADR

Sale

200

73.5100 USD

ADR

Sale

200

73.5600 USD

ADR

Sale

100

73.5700 USD

ADR

Sale

100

73.5900 USD

ADR

Sale

100

73.6000 USD

ADR

Sale

100

73.6000 USD

ADR

Sale

200

73.6000 USD

ADR

Sale

200

73.6100 USD

ADR

Sale

100

73.6200 USD

ADR

Sale

41

73.6300 USD

ADR

Sale

100

73.6400 USD

ADR

Sale

300

73.6400 USD

ADR

Sale

100

73.6400 USD

ADR

Sale

200

73.6500 USD

ADR

Sale

88

73.6700 USD

ADR

Sale

100

73.6700 USD

ADR

Sale

100

73.6700 USD

ADR

Sale

100

73.6800 USD

ADR

Sale

100

73.7200 USD

ADR

Sale

100

73.7200 USD

ADR

Sale

100

73.7200 USD

ADR

Sale

100

73.7300 USD

ADR

Sale

100

73.7500 USD

ADR

Sale

100

73.7600 USD

ADR

Sale

200

73.7900 USD

ADR

Sale

100

73.8000 USD

ADR

Sale

100

73.8400 USD

ADR

Sale

100

73.8900 USD

ADR

Sale

100

73.9200 USD

ADR

Sale

400

73.9400 USD

ADR

Sale

100

73.9400 USD

ADR

Sale

100

73.9500 USD

ADR

Sale

100

73.9500 USD

ADR

Sale

100

74.0100 USD

ADR

Sale

100

74.0200 USD

ADR

Sale

100

74.0300 USD

ADR

Sale

100

74.0300 USD

ADR

Sale

100

74.0600 USD

ADR

Sale

100

74.0900 USD

ADR

Sale

200

74.0900 USD

ADR

Sale

47

74.1100 USD

ADR

Sale

100

74.1100 USD

ADR

Sale

53

74.1100 USD

ADR

Sale

100

74.1200 USD

ADR

Sale

100

74.1300 USD

ADR

Sale

100

74.1500 USD

ADR

Sale

68

74.1900 USD

ADR

Sale

100

74.1900 USD

ADR

Sale

100

74.1900 USD

ADR

Sale

100

74.1900 USD

ADR

Sale

32

74.1900 USD

ADR

Sale

100

74.2300 USD

ADR

Sale

100

74.3000 USD

ADR

Sale

100

74.3000 USD

ADR

Sale

100

74.3700 USD

ADR

Sale

26

74.3800 USD

ADR

Sale

100

74.3900 USD

ADR

Sale

16

74.4000 USD

ADR

Sale

100

74.4300 USD

ADR

Sale

200

74.4300 USD

ADR

Sale

100

74.5000 USD

ADR

Sale

100

74.5000 USD

ADR

Sale

100

74.5000 USD

ADR

Sale

200

74.5300 USD

ADR

Sale

200

74.5900 USD

ADR

Sale

100

74.6100 USD

ADR

Sale

100

74.6200 USD

ADR

Sale

100

74.7200 USD

ADR

Sale

100

74.7200 USD

ADR

Sale

100

74.7400 USD

ADR

Sale

100

74.7400 USD

ADR

Sale

100

74.7500 USD

ADR

Sale

55

74.7600 USD

ADR

Sale

100

74.8000 USD

ADR

Sale

100

74.8200 USD

ADR

Sale

200

74.8700 USD

ADR

Sale

100

74.9600 USD

ADR

Sale

100

74.9600 USD

ADR

Sale

100

74.9600 USD

ADR

Sale

200

74.9700 USD

ADR

Sale

100

75.1300 USD

 

 

 

Class of relevant security

Purchases/sales

Total number of securities

ADR

Purchases

13,179

ADR

Sales

12,974

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES

 

 

Date of disclosure:

22 May 2014

Contact name:

Aadithya Rao and Yiannis Bardis

Telephone number:

+44(20) 7051 9046 / +44(20) 7774 7107

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

SUPPLEMENTAL FORM 8(OPEN POSITIONS)

 

DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENT TO

PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

Identity of the person whose open positions are being disclosed:

(GS) GOLDMAN, SACHS & CO.

Name of offeror/offeree in relation to whose relevant securities disclosure relates:

ASTRAZENECA PLC

 

 

2. OPTIONS AND DERIVATIVES

 

Class of relevant security

Product description e.g. call option

Written or purchased

Number of securities to which option or derivative relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

USD 0.25 ordinary

Call Option

Sold

100

75.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Call Option

Sold

200

45.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

200

80.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Call Option

Purchased

300

72.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

500

80.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

600

60.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

600

70.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Call Option

Purchased

800

67.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Sold

800

67.5000 USD

AMER

18/10/2014

USD 0.25 ordinary

Call Option

Sold

1,000

90.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

1,100

70.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Call Option

Purchased

1,200

72.5000 USD

AMER

18/10/2014

USD 0.25 ordinary

Call Option

Sold

1,300

62.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

1,300

67.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

1,600

65.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

1,600

67.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

1,700

62.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

1,800

70.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

1,800

75.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Call Option

Purchased

2,000

55.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

2,400

75.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

2,400

77.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

2,600

67.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

2,700

57.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

2,800

65.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Call Option

Purchased

2,900

77.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Sold

3,100

60.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Call Option

Purchased

3,100

75.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

3,300

75.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

3,300

85.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

3,500

72.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

4,600

65.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

5,400

75.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

7,100

72.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Sold

7,400

70.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

9,400

80.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

11,100

65.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

15,400

72.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Sold

15,800

62.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

16,600

70.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

18,100

60.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Sold

21,900

70.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

32,500

80.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

33,300

60.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

43,200

70.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Sold

100,000

70.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

100,000

75.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

100,000

77.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

100,000

80.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

138,300

70.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Call Option

Purchased

153,900

80.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

165,100

60.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Call Option

Purchased

200,000

40.0000 GBP

AMER

20/06/2014

USD 0.25 ordinary

Call Option

Purchased

200,000

40.0000 GBP

AMER

20/06/2014

USD 0.25 ordinary

Call Option

Sold

200,000

40.0000 GBP

AMER

20/06/2014

USD 0.25 ordinary

Call Option

Purchased

237,800

65.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Call Option

Purchased

338,800

70.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Purchased

100

35.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

100

40.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Purchased

100

40.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Purchased

100

47.5000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Purchased

200

30.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

200

37.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

300

70.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

300

75.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

500

52.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

600

57.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

600

65.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

900

27.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

900

32.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

900

70.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Purchased

1,000

55.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Purchased

1,000

60.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

1,000

60.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Put Option

Sold

1,200

67.5000 USD

AMER

18/10/2014

USD 0.25 ordinary

Put Option

Sold

1,200

72.5000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Sold

1,300

40.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

2,100

30.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Purchased

2,100

50.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

2,100

65.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Put Option

Sold

2,300

52.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

2,400

35.0000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Purchased

2,600

57.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Sold

2,600

65.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

3,100

67.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

3,600

70.0000 USD

AMER

18/10/2014

USD 0.25 ordinary

Put Option

Sold

3,900

52.5000 USD

AMER

15/01/2016

USD 0.25 ordinary

Put Option

Sold

4,100

70.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Purchased

4,300

60.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Sold

4,700

42.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

5,000

25.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

5,100

47.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

5,200

45.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Purchased

5,900

62.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Purchased

6,400

50.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

7,100

65.0000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Purchased

7,500

60.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

7,600

67.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Purchased

8,600

55.0000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

10,000

55.0000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

10,400

62.5000 USD

AMER

17/01/2015

USD 0.25 ordinary

Put Option

Sold

11,600

57.5000 USD

AMER

19/07/2014

USD 0.25 ordinary

Put Option

Sold

16,300

62.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Put Option

Purchased

25,000

38.0000 GBP

EURO

20/06/2014

USD 0.25 ordinary

Put Option

Sold

92,500

62.5000 USD

AMER

21/06/2014

USD 0.25 ordinary

Swap

Purchased

160

0.0000

N/A

08/04/2015

 

 

3. AGREEMENTS TO PURCHASE OR SELL

 

Full details should be given so that the nature of the interest or position can be fully understood:

 

It is not necessary to provide details on a Supplement form (Open Positions) with regard to contracts for differences ("CFD") or spread bets

 

 The currency of all pieces and other monetary amounts should be stated.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOATMMTMBTTBRI
Date   Source Headline
14th Apr 20207:00 amRNSTagrisso adjuvant trial overwhelmingly positive
14th Apr 20207:00 amRNSKoselugo (selumetinib) approved in the US for NF1
2nd Apr 20207:00 amRNSAstraZeneca divestment of Movantik completed
1st Apr 20203:00 pmRNSTotal Voting Rights
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:01 amRNSImfinzi approved in US for small cell lung cancer
30th Mar 20207:00 amRNSFarxiga CKD trial early stop for positive efficacy
26th Mar 20207:00 amRNSLokelma approved in Japan for hyperkalaemia
26th Mar 20207:00 amRNSDirector/PDMR Shareholding
24th Mar 20204:41 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 202012:02 pmRNSPrice Monitoring Extension
23rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:36 pmRNSPrice Monitoring Extension
23rd Mar 202012:08 pmRNSSecond Price Monitoring Extn
23rd Mar 202012:03 pmRNSPrice Monitoring Extension
20th Mar 202010:20 amRNSSecond Price Monitoring Extn
20th Mar 202010:15 amRNSPrice Monitoring Extension
20th Mar 20207:00 amRNSDirector/PDMR Shareholding
19th Mar 20207:00 amRNSLynparza granted orphan drug designation in Japan
17th Mar 20207:00 amRNSImfinzi confirmed overall survival in CASPIAN
13th Mar 20204:35 pmRNSPrice Monitoring Extension
12th Mar 202011:00 amRNSNotice of AGM
12th Mar 20207:00 amRNSUpdate on Phase III GY004 trial for cediranib
10th Mar 20207:00 amRNSDirector/PDMR Shareholding
6th Mar 20207:00 amRNSUpdate on Phase III DANUBE trial in bladder cancer
4th Mar 20207:00 amRNSFiling of Form 20-F with SEC
3rd Mar 202011:00 amRNSAnnual Financial Report
2nd Mar 20203:00 pmRNSTotal Voting Rights
2nd Mar 20207:00 amRNSDivestment of hypertension medicines completed
27th Feb 20207:00 amRNSDirector/PDMR Shareholding
25th Feb 20207:00 amRNSAstraZeneca divests global rights to Movantik
19th Feb 20207:00 amRNSDirector/PDMR Shareholding
14th Feb 20207:00 amRNSAZN: Full-year and Q4 2019 results
3rd Feb 20203:00 pmRNSTotal Voting Rights
27th Jan 20207:00 amRNSEnhertu Phase II trial met primary endpoint
27th Jan 20207:00 amRNSBrilinta met primary endpoint in stroke trial
27th Jan 20207:00 amRNSAstraZeneca divests hypertension medicines
27th Jan 20207:00 amRNSAstraZeneca to recover brazikumab (MEDI2070)
20th Jan 20207:00 amRNSImfinzi, tremelimumab granted ODD in liver cancer
20th Jan 20207:00 amRNSFDA grants Lynparza Priority Review for PROfound
13th Jan 20207:01 amRNSLynparza granted FDA Priority Review for PAOLA-1
13th Jan 20207:00 amRNSUpdate on Epanova Phase III STRENGTH trial
6th Jan 20207:01 amRNSFarxiga granted FDA heart failure Priority Review
6th Jan 20207:00 amRNSLokelma approved in China for hyperkalaemia
2nd Jan 20203:00 pmRNSTotal Voting Rights
30th Dec 20197:00 amRNSUS FDA approved Lynparza for pancreatic cancer
23rd Dec 20197:00 amRNSTriple-combination approved in China for COPD
23rd Dec 20197:00 amRNSEnhertu (trastuzumab deruxtecan) approved in US
20th Dec 20197:00 amRNSAstraZeneca divests rights to Arimidex and Casodex

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.